drugset
drugset / Trial / NCT04732468

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

NCT04732468 ↗

Phase 1 Terminated 28 enrolled ImmunityBio, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) and to select an optimal combination dose for future studies.

Timeline

Start
2021-02-24
Primary completion
2022-07-11
Completion
2023-01-09

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to low enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject hAd5-S-Fusion+N-ETSD Vaccine — Subcutaneous

Indications

COVID-19